NCT03709563终止不适用
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of an Oral Nutraceutical Supplement With Standardized Botanicals in Males With Self-Perceived Thinning Hair and Loss
适应症
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 74
- 试验地点
- 2
- 主要终点
- Hair counts
研究概览
简要总结
Hair loss study in men with self-perceived thinning hair and loss
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 21 Years 至 45 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Males between 21-45 years of age, inclusive
- •Have self-reported thinning or hair loss for more than 3 months prior to screening
- •Clinically confirmed to have hair loss or thinning by the investigator via physical exam, including subjects with male pattern hair loss with frontal and vertex patterns II, IIIv or IV using the Norwood Hamilton Hair Loss Scale (NHS).
- •In good general health, as determined by the Investigator
- •Willing and able to attend all study visits
- •Willing to maintain the same hair style as at the Screening Visit for the duration of the study.
- •Willing to use a mild non-medicated shampoo and conditioner for the duration of the study (medicated shampoo and conditioner refer to any prescription shampoo or conditioner as well as any over-the counter medicated shampoo or conditioner, such as those for treatment of dandruff or promoting hair growth)
- •Be willing and able to cooperate with the requirements of the study.
- •Voluntarily sign and date an informed consent agreement approved by the Institutional Review Board.
- •Be able to complete and understand the various rating instruments in English.
排除标准
- •Clinical diagnosis of alopecia areata or scarring forms of alopecia
- •Scalp hair loss on the treatment area, due to disease, injury, or medical therapy
- •Current skin disease (e.g., psoriasis, atopic dermatitis, skin cancer, eczema, sun damage, seborrheic dermatitis), cuts and or abrasions on the scalp or condition (e.g., sunburn, tattoos) on the treatment area that, in the opinion of the Investigator, might put the subject at risk or interfere with the study conduct or evaluations.
- •History of surgical correction of hair loss on the scalp (i.e. Hair transplant).
- •Use of any products or devices purported to promote scalp hair growth (e.g., finasteride or minoxidil) within the 6 months prior to the Baseline Visit.
- •Use of anti-androgenic therapies (e.g., spironolactone, flutamide, cyproterone acetate, progesterone, and bicalutamide) within 3 months prior to the Baseline Visit.
- •History of burning, flaking, itching, and stinging of the scalp.
- •History of malignancy (except cutaneous squamous cell carcinoma and basal cell carcinoma) or currently undergoing chemotherapy or radiation treatments.
- •A known history of autoimmune thyroid disease, any other thyroid disorder/abnormality or other autoimmune disorders that in the opinion of the Investigator may interfere with the study treatment.
- •A known history of depression or bipolar disease or any other condition that may impact the subject's participation in the opinion of the investigator.
- •Recent utilization of low level lasers for hair growth.
- •Any condition that the Investigator thinks may put the Subject at risk or interfere with their participation in the study.
- •Known history or recent blood work indicating iron deficiency, bleeding disorders or platelet dysfunction syndrome as well as subjects receiving anticoagulant therapy or smokers with usage >20 cigarettes/day.
- •Use of any medications that are known to potentially cause hair loss or affect hair growth, as determined by the Investigator.
结局指标
主要结局
Hair counts
时间窗: Day 90, 180, 270, 360
The change in vellus and terminal hair counts / average number of hairs (N/cm2) within 2 ROIs
次要结局
- Hair density(Day 90, 180, 270, 360)
- Shaft Thickness(Day 90, 180, 270, 360)
研究者
研究点 (2)
Loading locations...
相似试验
进行中（未招募）
1 期
Study on the effect of 12 weeks of treatment with tadalafil in patients with symptoms of lower urinary tract secondary to hypertrophy of the prostate.lower urinary tract symptoms/benign prostatic hyperplasiaMedDRA version: 17.1Level: PTClassification code 10071289Term: Lower urinary tract symptomsSystem Organ Class: 10038359 - Renal and urinary disordersMedDRA version: 17.1Level: PTClassification code 10004446Term: Benign prostatic hyperplasiaSystem Organ Class: 10038604 - Reproductive system and breast disordersEUCTR2014-004422-17-ITIVERSITY OF FLORENCE86
已完成
不适用
Randomised, double-blind, controlled study of combined spinal epidural (CSE) analgesia for labour with and without epidural volume extension (EVE).ISRCTN21230935Record Provided by the NHSTCT Register - 2004 Update - Department of Health (UK)
进行中（未招募）
1 期
A Double-Blind Placebo-Controlled Pilot Study of the Safety and Tolerability of AIMSPRO in established Diffuse Cutaneous Systemic Sclerosis - Pilot study of AIMSPRO in diffuse cutaneous systemic sclerosisEUCTR2007-003122-24-GBDaval International Limited20
进行中（未招募）
不适用
The effect of a novel drug (CCX140-B) on albuminuria in patients with type 2 diabetes mellitusType 2 Diabetes Mellitus, nephropathy, albuminuriaMedDRA version: 14.0Level: HLTClassification code 10012602Term: Diabetes mellitus (incl subtypes)System Organ Class: 10014698 - Endocrine disordersMedDRA version: 14.0Level: PTClassification code 10027525Term: MicroalbuminuriaSystem Organ Class: 10038359 - Renal and urinary disordersMedDRA version: 14.0Level: PTClassification code 10061835Term: Diabetic nephropathySystem Organ Class: 10038359 - Renal and urinary disordersMedDRA version: 14.0Level: PTClassification code 10001580Term: AlbuminuriaSystem Organ Class: 10038359 - Renal and urinary disordersMedDRA version: 14.0Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2011-003049-16-NLChemoCentryx, Inc
已完成
2 期
A Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Effect of CCX140-B on Albuminuria in Subjects with Type 2 Diabetes Mellitusalbuminuriaprotein in urine1001265310029149NL-OMON38004Chemocentryx24